Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: J Vasc Interv Radiol. 2018 Mar 14;29(6):850–857.e1. doi: 10.1016/j.jvir.2018.01.769

Table 1.

Training Cohort: Patient, Disease, and Treatment Characteristics

Parameter N (%) Parameter N (%)
Number of Patients 36 Sorafenib
Transplant recipient
Distant Metastasis
Lymph Node Metastasis
Hepatitis B
Hepatitis C
Cirrhosis
Ascites
Encephalopathy
8 (22.2)
5 (13.9)
2 (5.6)
3 (8.3)
3 (8.3)
28 (77.8)
5 (13.9)
5 (13.9)
2 (5.6)
Treatment Modality
 Conventional TACE 30 (83)
 DEE-TACE 6 (17)
Gender
 Male 31 (86.1)
 Female 5 (13.9) BCLC stage
Race  0 1 (2.8)
 White 23 (63.9)  A 12 (33.3)
 African American 8 (22.2)  B 10 (27.8)
 Asian/Pacific Islander 2 (5.6)  C 13 (36.1)
 Other 3 (8.3)
ECOG Performance Status Parameter Mean (SD)
 0 24 (66.7) Albumin 3.98 (0.5)
 1 10 (27.8) Bilirubin 0.9 (0.5)
 2 2 (5.5) INR 1.1 (0.1)
Child Pugh Class Tumor Size (cm) 5.2 (3.0)
 A 31 (86.1) Number of Tumors 2.6 (1.1)
 B 4 (11.1) Age 62.0 (8.9)
 C 1 (2.8)

Clinical, disease, and treatment characteristics of the patient cohort used to train the machine learning model. Liver transplantation occurred strictly after TACE in all patients who were transplanted.

Abbreviations: trans-arterial chemoembolization, TACE; drug-eluting embolic agents, DEE; standard deviation, SD; Barcelona Clinic Liver Cancer, BCLC